SCHEMBL70702

SCHEMBL70702

COC(=O)c1ccc(Br)s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.63
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
NPSR1 Q6W5P4 4/20 0.56
PPARG P37231 2/20 0.56
NCOA1 Q15788 2/20 0.56
NCOA3 Q9Y6Q9 2/20 0.56
LMNA P02545 1/20 0.56
NCOA2 Q15596 1/20 0.56
GSK3B P49841 2/20 0.52
HPGD P15428 3/20 0.50
MAPK1 P28482 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 1/20 0.50
ATM Q13315 1/20 0.50
GAA P10253 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
USP2 O75604 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KDM4E B2RXH2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23407055 0.89 NPSR1 (0.50) DAOCES2CES1NPSR1PPARG
SCHEMBL70027 0.84 NPSR1 (0.67) DAONPSR1PPARGNCOA1NCOA3
SCHEMBL7651777 0.83 CES2 (0.64) DAOCES2CES1NPSR1PPARG
SCHEMBL64687 0.79 HDAC3 (0.58) DAOCES2CES1NPSR1PPARG
SCHEMBL5043396 0.79 CES2 (0.53) DAOCES2CES1NPSR1PPARG
SCHEMBL1235256 0.78 LMNA (0.60) NPSR1PPARGNCOA1NCOA3LMNA
SCHEMBL1303016 0.78 NPSR1 (0.60) DAONPSR1PPARGNCOA1NCOA3
SCHEMBL71972 0.78
SCHEMBL3347072 0.77 GSK3B (0.59) DAOCES2CES1NPSR1PPARG
SCHEMBL3958438 0.77 HDAC3 (0.57) DAOCES2CES1NPSR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118620231-B Luminescent metal organic frame material, preparation method thereof and application thereof in nitrofuran antibiotic detection 江苏师范大学 2024-11-15 CN claimed
CN-118620231-A Luminescent metal organic frame material, preparation method thereof and application thereof in nitrofuran antibiotic detection 江苏师范大学 2024-09-10 CN claimed
CN-116239586-A Thienyl-containing organic semiconductor crystal material and preparation method and application thereof 宁波大学 2023-06-09 CN claimed
CN-114044905-B Preparation method of end-group functionalized polydimethylsiloxane 复旦大学 2023-01-06 CN claimed
CN-115403601-A Microenvironment sensitive fluorescent dye for detecting A beta fibril and preparation method thereof 常州工学院 2022-11-29 CN claimed
CN-114044905-A Preparation method of end group functionalized polydimethylsiloxane 复旦大学 2022-02-15 CN claimed
CN-105111197-B Synthesis method of raltitrexed 上海鼎雅药物化学科技有限公司 2021-05-04 CN claimed
EP-3747957-A1 FLUORESCENT VINYL TIOPHENE AND BITIOPHENE COUMARINS DYES AND METHOD OF SYNTHESIS THEREOF Universidade de Évora (PT) 2020-12-09 EP claimed
WO-2026086812-A1 INHIBITORS OF MENIN RONGCHANG PHARMACEUTICALS, LTD. (CN) 2026-04-30 WO disclosed
WO-2026086915-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR (GIPR) ANTAGONISTS AND METHODS OF USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2026-04-30 WO disclosed
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS AURIGENE ONCOLOGY LTD (IN) 2025-11-27 US disclosed
EP-4650002-A1 ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) Ludwig-Maximilians-Universität (DE) 2025-11-19 EP disclosed
US-12410193-B2 Bicyclic heterocyclyl derivatives as IRAK4 inhibitors AURIGENE ONCOLOGY LIMITED (IN) 2025-09-09 US disclosed
EP-4573092-A1 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER Olema Pharmaceuticals, Inc. (US) 2025-06-25 EP disclosed
EP-0679630-A1 Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1995-11-02 EP disclosed
EP-0674516-A4 1995-10-25 EP disclosed
EP-0674516-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1995-10-04 EP disclosed
US-5434180-A Skin disorders; retinoid activity; rheumatoid psoriasis; CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1995-07-18 US disclosed
WO-1994013295-A1 ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS AGOURON PHARMACEUTICALS, INC. (US) 1994-06-23 WO disclosed
US-5124473-A Skin disorders; antiinflammatory agents, antiallergens CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1992-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410193-B2 Bicyclic heterocyclyl derivatives as IRAK4 inhibitors IRAK4, IRAK3, IRAK1 DAO 3454/4885CES2 2503/4885CES1 834/4885
US-20250361244-A1 BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS IRAK4, IRAK3, IRAK1 DAO 3454/4885CES2 2503/4885CES1 834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.